Log In
Print
BCIQ
Print
Print this Print this
 

CF-404

  Manage Alerts
Collapse Summary General Information
Company ContraFect Corp.
DescriptionCombination of human mAbs CF-401, which targets Type A; Group 1 influenza; CF-402, which targets Type A; Group 2 influenza; and CF-403, which targets Type B influenza
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationInfluenza virus
Indication DetailsTreat seasonal and pandemic influenza infections
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today